CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cadrenal Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.06−0.03 (-2.75%)
Close on Oct 19, 2026
- Market cap
- $3.09M
- P/E (TTM)
- –
- Dividend yield
- 1556.60%
Cadrenal Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Market Cap | $3.78M | $197.05M |
| Enterprise Value | $1.39M | $106.56M |
| PB Ratio | 0.92 | 2.14 |
| P/TBV Ratio | 0.92 | 2.46 |
Income (trailing twelve months)
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$11.65M | -$21.44M |
| Net Income | -$11.54M | -$22.46M |
| EBITDA | -$11.65M | -$16.91M |
| EPS (Diluted) | -$4.92 | -$0.83 |
Returns
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -275.2% | -53.1% |
| Return on Assets (ROA) | -199.6% | -41.0% |
| Return on Invested Capital (ROIC) | -4264.6% | -32.0% |
| Return on Capital Employed (ROCE) | -284.8% | -37.8% |
Balance sheet
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.39M | $62.42M |
| Net Cash (Debt) | $2.39M | $15.68M |
| Net Cash Per Share | $0.67 | $0.65 |
| Equity (Book Value) | $4.09M | $48.79M |
| Book Value Per Share | $1.15 | $1.36 |
| Tangible Book Value | $4.09M | $23.06M |
| Working Capital | $4.09M | $75.77M |
Financial position
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.73 | 3.30 |
| Quick Ratio | 1.60 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.16M | -$12.35M |
Efficiency
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.31M | -$732.08K |
| Employee Count | 5 | 73 |
Dividends and yields
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -305.3% | -21.2% |
| Dividend Yield | 1556.6% | 1.83% |
| Buyback Yield | -78.6% | -0.58% |
| Shareholder Yield | 1478.0% | 0.00% |
| Dividend Per Share | $16.50 | $0.83 |
| Dividend Growth (YoY) | 0.00% | 2.37% |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 3,567,590 | 59,128,900 |
| Shares Change (YoY) | 55.9% | 11.1% |
| Shares Change (QoQ) | 23.6% | 0.54% |
| Float | 2,440,090 | 48,744,500 |
| Shares Held by Insiders | 31.6% | 11.8% |
| Shares Held by Institutions | 3.15% | 59.4% |
Scores
| Measure | Cadrenal Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -15.70 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Cadrenal Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.